According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease.
Read the full article at the link in our bio!
Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.